Akademik Veri Yönetim Sistemi
ISPOR 2022, Washington, Amerika Birleşik Devletleri, 15 - 18 Mayıs 2022, ss.193, (Özet Bildiri)
OBJECTIVE: The
introduction of immunotherapy treatments in oncology offers new opportunities
and the hope to turn cancer into a chronic disease. However, there is
widespread uncertainty regarding the ability of existing budgets to accommodate
these costs. The overall objective of this study is to estimate the potential
health and economic impact of introducing the PD-1/PD-L1 inhibitors in Turkey.
METHODS: The
Health Impact Projection (HIP) Model has been developed for estimating the
health and economic impact of the PD-1/PD-L1 inhibitor class compared to Standard
of Care (SoC). The adaptation of HIP
model for Turkey is focusing on 7 cancer types (Melanoma, Non-Small Cell and
Small Cell Lung Cancer, Bladder Cancer, Head and Neck Cancer, Renal Cell
Carcinoma and Triple Negative Breast Cancer) that have been assessed over a
time frame of 5 years (2021–2025).
Key outcomes include Overall Survival, Life Years
Gained, Quality of Life Years Gained and Budget Impact. The assessment of the
relative health and cost benefits were based on publicly available data sources,
scientific literature, and expert opinion.
RESULTS: Results show that over the next five years, the
class of PD-1/PD-L1 inhibitors is expected to deliver to 118,128 patients in
Turkey a gain of 23,345 additional life years whilst simultaneously preventing
over 14,586 adverse events (AEs) with a budget impact of approximately €1,871 million
versus the current SoC treatments.
CONCLUSIONS:
The PD-1/PD-L1 inhibitors can deliver significant survival and life years
benefits to the Turkish population with less severe AEs. The 5-year economic impact
of these drugs is manageable and represents 1.67% of the expected total
healthcare expenditure. The HIP model might help to reduce the uncertainty and
inform the decision-makers on the health and economic impact of PD-1/PD-L1
inhibitors in different scenarios in Turkey to facilitate continued access to
these innovative treatments over time.